Small molecular glucokinase activators: Has another new anti-diabetic therapeutic lost favour?

British Journal of Pharmacology

Volumn 168, Issue 2, 2013, Pages 335-338

  Rees, Matthew G ^a,b   Gloyn, Anna L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

glucokinase; glucokinase activator; glucokinase regulatory protein; hepatic steatosis; hepatopharmacology; triglycerides; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOKINASE REGULATORY PROTEIN; GLUCOSE; HEMOGLOBIN A1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SAFETY; FATTY LIVER; GCKR GENE; GENOTYPE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GSK GENE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATORS; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84871586858     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02201.x     Document Type: Review

References (16)

1. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, et al,. (2009). The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18: 4081-4088.
2. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, et al,. (2010). Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95: 5028-5036.
3. De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, Umbdenstock T, et al,. (2012). Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Brit J Pharmacol 168: 339-353.
4. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al,. (2010). New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105-116.
5. Ferre T, Riu E, Franckhauser S, Agudo J, Bosch F, (2003). Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 46: 1662-1668.
6. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, et al,. (2003). Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373.
7. International Diabetes Federation (2011). IDF Diabetes Atlas, International Diabetes Federation (Ed), 5th Edn. International Diabetes Federation: Brussels.
8. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP, et al,. (2012). Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 44: 269-276.
9. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, et al,. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560-2566.
10. Nissim I, Horyn O, Daikhin Y, Wehrli SL, Yudkoff M, Matschinsky FM, (2012). Effects of a glucokinase activator on hepatic intermediary metabolism: study with (13)C-isotopomer-based metabolomics. Biochem J 444: 537-551.
11. O'Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB, (1999). Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022-2027.
12. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S, et al,. (2009). Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 1512-1526.
13. Rees MG, Wincovitch S, Schultz J, Waterstradt R, Beer NL, Baltrusch S, et al,. (2012). Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55: 114-122.
14. Saxena R, Voight BF, Lyssenko V, Burtt NP, de, Bakker PI, Chen H, et al,. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331-1336.
15. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al,. (2011). Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7: e1001324.
16. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B, et al,. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature 477: 54-60.